Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.
Business. Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.
Analyst recommendations
9 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Yunnan Baiyao Group Co Ltd operates in the health care sector, specifically within the pharmaceuticals industry, generating revenue through the sale of healthcare products and services.
Yunnan Baiyao maintains a conservative capital structure with a debt-to-equity ratio of 0.03 and a current ratio of 2.64, indicating strong short-term liquidity coverage. The company holds total equity of 40.04 billion CNY against total liabilities of 14.22 billion CNY. Despite the strong balance sheet, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt, suggesting that cash and equivalents are lower than total debt obligations. The company generated 4.60 billion CNY in operating cash flow, which comfortably covers its capital expenditure of 480 million CNY, resulting in free cash flow of 1.04 billion CNY.
Profitability metrics demonstrate efficient capital utilization, with a return on equity of 12.87% and a return on assets of 9.50%. The company trades at a price-to-earnings ratio of 16.84 and an EV/EBITDA of 14.57, reflecting a moderate valuation multiple relative to its earnings power. The price-to-book ratio stands at 2.17, indicating the market values the company's tangible assets at a premium. Operating income of 6.04 billion CNY on revenue of 41.19 billion CNY suggests a stable operating margin, supported by gross profit of 11.90 billion CNY.
Segment and geographic revenue breakdowns are not provided in the available data, preventing a detailed analysis of revenue concentration or regional exposure. The analysis relies on consolidated financial figures, which show a broad revenue base of 41.19 billion CNY. Without segment data, it is not possible to assess the contribution of specific product lines or geographic markets to the overall financial performance.
Historical growth trajectory data is absent from the input, limiting the ability to evaluate long-term revenue trends or earnings consistency. The current financial snapshot provides a static view of the company's performance, with net income of 5.15 billion CNY. The lack of historical period data prevents a year-over-year or quarter-over-quarter growth analysis, leaving the growth narrative reliant on current period metrics alone.
Risk assessment indicates low dilution risk, supported by the fact that basic and diluted shares outstanding are identical at 1.78 billion shares. The key flag regarding negative net cash after debt subtraction warrants monitoring, as it may impact financial flexibility despite the low leverage ratio. The medium liquidity risk rating suggests potential constraints in meeting short-term obligations under stress scenarios, although the current ratio of 2.64 provides a buffer.
Recent investor relations observations show strong analyst sentiment, with a mean recommendation of 1.78 (where 1 is strong buy) and a mean price target of 70.01 CNY, implying significant upside from the current market price of 48.65 CNY. The high price target of 82.20 CNY and low of 64.00 CNY indicate a consensus view of undervaluation. There are no hold ratings among the analysts, with 2 strong buys and 7 buys recorded, reflecting positive market expectations for the company's future performance.
- Strong balance sheet with low leverage (debt-to-equity 0.03) and high current ratio (2.64) supports financial stability.
- Analyst consensus is bullish with a mean price target of 70.01 CNY, suggesting 44% upside from the current price of 48.65 CNY.
- Profitability is solid with ROE of 12.87% and ROA of 9.50%, indicating efficient use of assets and equity.
- Negative net cash position after debt subtraction is a key risk flag despite low overall debt levels.
- Low dilution risk is confirmed by identical basic and diluted share counts.
- Lack of segment and historical data limits the depth of growth and concentration analysis.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 3,18 |
| Revenue | —no estimate | —no estimate | 42,6B CNY |
| Operating income | —no estimate | —no estimate | 5,9B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Ev To Operating Incomeenterprise_value / operating_income
- Yunnan Baiyao Group Co Ltd Market data — financials · 2026-07-08
- Yunnan Baiyao Group Co Ltd Market data — analyst estimates · 2026-07-08
- Yunnan Baiyao Group Co Ltd Market data — ESG · 2026-07-08
Ownership & reference
Leadership
- Hongshen LiSenior Vice President
- Ming DongPresident, Chief Executive Officer, Director
- Shengli LiSenior Vice President